+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies

Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies

Cancer Investigation 28(8): 839-848

The receptor tyrosine kinase inhibitors, imatinib and sunitinib, have significantly improved the prognosis for patients with advanced gastrointestinal stromal tumors (GISTs). Most GISTs exhibit mutations in the genes encoding the stem cell factor receptor (KIT) or platelet-derived growth factor receptor alpha (PDGFRA). Imatinib is more effective in patients with KIT exon 11 mutations compared with KIT exon 9 mutations and wild-type genotype, while sunitinib confers greater in vitro efficacy in patients with KIT exon 9 mutants and wild-type genotype than in KIT exon 11 mutants. This review examines the potential role of mutational analysis to optimize therapy with imatinib and sunitinib for GIST.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053737998

Download citation: RISBibTeXText

PMID: 20690803

DOI: 10.3109/07357907.2010.494322

Related references

Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach. Oncology Research and Treatment 39(12): 811-816, 2016

Targeted therapies in gastrointestinal stromal tumors. Seminars in Diagnostic Pathology 25(4): 295-303, 2008

Correlation between mutational types and targeted treatment in gastrointestinal stromal tumors. Zhonghua Bing Li Xue Za Zhi 37(8): 555-558, 2010

Clinical, Pathologic, and Immunohistochemical Characteristics of Gastrointestinal Stromal Tumors of the Colon and Rectum: Implications for Surgical Management and Adjuvant Therapies. Yearbook of Gastroenterology 2007: 59-60, 2007

Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Diseases of the Colon and Rectum 49(5): 609-615, 2006

Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Pathology Research International 2011: 708596, 2011

Predictors of response to targeted therapies for gastrointestinal stromal tumors. Archives of Pathology and Laboratory Medicine 136(5): 483-489, 2012

Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers. Biochemical Pharmacology 80(5): 575-583, 2010

Gastrointestinal stromal tumors (GIST): at the forefront of targeted therapies. Medecine Sciences 29(6-7): 630-636, 2013

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget 6(4): 1954-1966, 2015

Gastrointestinal stromal tumors A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?. Asia-Pacific Journal of Clinical Oncology 4(4): 185-187, 2008

Underuse of exon mutational analysis for gastrointestinal stromal tumors. Journal of Surgical Research 231: 43-48, 2018

Mutational analysis of CASP1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 14 genes in gastrointestinal stromal tumors. Human Pathology 40(6): 868-871, 2009

Clinical implications of mutational analysis in gastrointestinal stromal tumours. British Journal of Cancer 98(4): 684-688, 2008

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematology/Oncology Clinics of North America 27(5): 905-920, 2014